Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts. Show More...
-
Website https://www.karyopharm.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 7.87 EUR
-
Last Updated 04-03-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share USD -1.05 -1.62 -5.59 -2.43 -3.32 -2.92 -2.81 -3.14 -3.22 -2.91 Dividends USD Payout Ratio % * Shares Mil 10.0 10.0 6.0 31.0 36.0 38.0 46.0 57.0 62.0 64.0 Book Value Per Share * EUR 5.73 5.63 3.77 2.39 2.46 0.82 2.06 Free Cash Flow Per Share * EUR -1.3 -2.3 -2.24 -1.67 -1.92 -2.94 Return on Assets % -142.73 -372.3 -42.56 -40.03 -54.24 -55.37 -71.52 -68.42 -62.75 -52.99 Financial Leverage (Average) 1.02 1.07 1.09 1.11 1.39 1.86 5.93 2.5 Return on Equity % -53.44 -41.9 -58.34 -60.77 -88.43 -114.13 -171.36 -129.67 Return on Invested Capital % -53.44 -41.95 -58.78 -61.2 -89.13 -69.32 -83.18 -66.55 Interest Coverage -70.55 -11.75 -8.72 Current Ratio 3.24 0.49 47.98 16.88 11.74 7.99 3.0 7.13 6.01 7.46 Quick Ratio 3.08 0.2 47.38 16.72 11.61 7.86 2.96 7.0 5.82 7.27 Debt/Equity 0.56 2.47 0.75